Results 141 to 150 of about 127,985 (250)

Impact of Nirsevimab on Respiratory Syncytial Virus PCR Test Positivity in Young Infants: A Community‐Level Observational Study in Queensland, Australia

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim In April 2024 nirsevimab, a long‐acting respiratory syncytial virus (RSV)‐specific monoclonal antibody, was made available free of charge to all newborn infants in Queensland. We aimed to explore the community‐level impact of a nirsevimab‐based prevention program on RSV detection percentages among infants aged ≤ 3 months in Queensland ...
Asmaa El‐Heneidy, Keith Grimwood, Jennifer M. Robson, Chanpaseuth Vicki Vilaylath, Sarah G. Cherian, Stephen B. Lambert, Robert S. Ware   +6 more
wiley   +1 more source

Nocturnal Hypoxemic Burden Predicts Mortality in Patients Awaiting Heart Transplantation

Journal of Sleep Research, EarlyView.
Trial design and results on hypoxemic burden in the context of heart transplantation. ABSTRACT Risk stratification for patients with end‐stage heart failure (HF) awaiting heart transplantation (HTX) is crucial. Sleep‐disordered breathing (SDB) is a prevalent comorbidity, yet the impact of its resultant hypoxemic burden remains unclear in this ...
Max Potratz, Tatevik Manukyan, René Schramm, Angelika Costard‐Jäckle, Uwe Fuchs, Michiel Morshuis, Sabina P. W. Guenther, Sebastian V. Rojas, Volker Rudolph, Jan F. Gummert, Henrik Fox   +10 more
wiley   +1 more source

Assessing the Impact of Wastewater Flow Rates on SARS‐CoV‐2 RNA Detection: Insights for Environmental Surveillance and Policymaking

Environmental Quality Management, Volume 35, Issue 4, Summer 2026.
We meta‐analyzed 10 studies to assess whether influent flow rate affects SARS‐CoV‐2 RNA detection in wastewater treatment plants serving ≤60,000 inhabitants. The pooled odds ratio (2.08; 95% CI: 0.994–37; p = 0.053) showed no significant association between flow rate and detection probability.
André Felipe Bendix, Alex Batista Trentin, Deborah Catharine De Assis Leite, Betty Cristiane Kuhn, Felipe Beijamini, Simone Wendt, Flavia Regina Oliveira de Barros, Naiana Cristine Gabiatti, Juliana Morini Küpper Cardoso, Nédia de Castilhos Ghisi   +9 more
wiley   +1 more source

Clinical Interventions During Inter‐hospital Transfer of Infants With Moderate‐to‐Severe Bronchiolitis: Implications for Advanced Nursing Practice

Nursing in Critical Care, Volume 31, Issue 3, May 2026.
ABSTRACT Background Bronchiolitis is a leading cause of hospitalisation and paediatric intensive care admissions in infants. Moderate‐to‐severe cases often require inter‐hospital transfer for respiratory support, usually organised by specialised paediatric emergency transport services (PETS).
Arthur Gaudaire, Christophe Milesi, Alexia Morel, Julien Baleine, Maliha Badr, Alexandra Deveze, Sylvain Paulhac, Marion Palpacuer, Gilles Cambonie, Arthur Gavotto   +9 more
wiley   +1 more source

Acute Respiratory Distress Syndrome in Adult Patient With RSV Infection: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT We described the case of a 54‐year‐old woman with no history of immunodeficiencies admitted to the ICU of our university hospital due to acute respiratory failure and ARDS secondary to severe community‐acquired pneumonia (sCAP) caused by RSV infection.
Gioacchina Martina Campione, Mario Alessio Guarano, Mariachiara Ippolito, Giulia Catalisano, Giulia Lo Scrudato, Ilenia Giacchino, Erika Mannino, Teresa Maria Assunta Fasciana, Giovanni Giammanco, Cesira Palmeri di Villalba, Santi Maurizio Raineri, Andrea Cortegiani, Antonino Giarratano   +12 more
wiley   +1 more source

Respiratory syncytial virus infection induces heterologous protection against SARS-CoV-2 through γδ T cell-mediated trained immunity and the activation of SARS-CoV-2-reactive mucosal T cells. [PDF]

J Virol
Adam A, Wu W, Jones MC, Hao H, Aditi, Samir P, Bao X, Wang T.   +7 more
europepmc   +1 more source

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 1036-1046, April 2026.
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu, Farina Hellmann, Xiaowei Zang, Nele Plock, Keyur Parmar, Radha A. Railkar, S. Y. Amy Cheung, Brian M. Maas, Ferdous Gheyas   +8 more
wiley   +1 more source

Incidence of respiratory syncytial virus and influenza: A Danish nationwide cohort study. [PDF]

Hum Vaccin Immunother
Fonseca MJ, Bratković S, Pedersen M, Kany M, Pliakas T, Reeves R, Marijam A, Turriani E, Vestergaard Dich N, Çolak Y, Helleberg M.   +10 more
europepmc   +1 more source

RSV nucleocapsid [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Besieging RSV [PDF]

Science-Business eXchange, 2009
openaire   +1 more source